Neurocrine Biosciences, Inc. $NBIX Shares Sold by Fiera Capital Corp

Fiera Capital Corp reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 490,594 shares of the company’s stock after selling 3,881 shares during the period. Fiera Capital Corp owned 0.49% of Neurocrine Biosciences worth $61,663,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Segall Bryant & Hamill LLC grew its position in shares of Neurocrine Biosciences by 13.3% in the 1st quarter. Segall Bryant & Hamill LLC now owns 53,103 shares of the company’s stock valued at $5,873,000 after buying an additional 6,233 shares during the last quarter. Grandfield & Dodd LLC lifted its position in Neurocrine Biosciences by 2.8% in the first quarter. Grandfield & Dodd LLC now owns 16,570 shares of the company’s stock valued at $1,833,000 after acquiring an additional 459 shares during the last quarter. Hussman Strategic Advisors Inc. boosted its stake in Neurocrine Biosciences by 200.0% in the first quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company’s stock valued at $2,787,000 after acquiring an additional 16,800 shares in the last quarter. Teachers Retirement System of The State of Kentucky grew its holdings in shares of Neurocrine Biosciences by 24.8% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 70,020 shares of the company’s stock worth $7,745,000 after purchasing an additional 13,900 shares during the last quarter. Finally, HighPoint Advisor Group LLC increased its position in shares of Neurocrine Biosciences by 15.0% during the first quarter. HighPoint Advisor Group LLC now owns 2,812 shares of the company’s stock worth $302,000 after purchasing an additional 366 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Down 0.3%

Shares of NASDAQ:NBIX opened at $146.85 on Thursday. The company has a market cap of $14.64 billion, a P/E ratio of 35.13, a PEG ratio of 0.94 and a beta of 0.22. Neurocrine Biosciences, Inc. has a 52 week low of $84.23 and a 52 week high of $157.67. The company has a 50-day moving average price of $142.55 and a 200 day moving average price of $132.33.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, October 28th. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.46. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The company had revenue of $794.90 million for the quarter, compared to analyst estimates of $746.61 million. During the same quarter in the prior year, the company earned $1.81 earnings per share. Neurocrine Biosciences’s revenue was up 27.8% compared to the same quarter last year. Analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

NBIX has been the subject of a number of research analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Wednesday, October 8th. Guggenheim increased their price objective on Neurocrine Biosciences from $165.00 to $175.00 and gave the company a “buy” rating in a report on Friday, August 1st. Canaccord Genuity Group raised their target price on shares of Neurocrine Biosciences from $160.00 to $164.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. JPMorgan Chase & Co. upped their price target on shares of Neurocrine Biosciences from $171.00 to $179.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Finally, Piper Sandler increased their price target on shares of Neurocrine Biosciences from $175.00 to $179.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus target price of $170.53.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director William H. Rastetter sold 18,000 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $151.82, for a total transaction of $2,732,760.00. Following the completion of the transaction, the director owned 40,360 shares in the company, valued at approximately $6,127,455.20. The trade was a 30.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kyle Gano sold 300 shares of the company’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total transaction of $42,591.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares in the company, valued at $19,933,581.79. This trade represents a 0.21% decrease in their position. The SEC filing for this sale provides additional information. 4.80% of the stock is currently owned by corporate insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.